GWP
CRSP icon

Gen-Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

Gen-Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$873 Hold
16
– – ﹤0.01% 671
2026
Q1 		$761 Hold
16
– – ﹤0.01% 679
2025
Q4 		$839 Hold
16
– – ﹤0.01% 645
2025
Q3 		$1.04K Hold
16
– – ﹤0.01% 631
2025
Q2 		$778 Hold
16
– – ﹤0.01% 596
2025
Q1 		$544 Hold
16
– – ﹤0.01% 580
2024
Q4 		$630 Hold
16
– – ﹤0.01% 615
2024
Q3 		$767 Hold
16
– – ﹤0.01% 623
2024
Q2 		$864 Hold
16
– – ﹤0.01% 602
2024
Q1 		$1.09K Buy
+16
New +$1.15K ﹤0.01% 582

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gen-Wealth Partners's CRSP Position: Q2 2026 in Review

Gen-Wealth Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 16 shares worth $873. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Gen-Wealth Partners first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.09K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Gen-Wealth Partners held 16 shares of CRISPR Therapeutics worth $873 as of Q2 2026.
  • Gen-Wealth Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #671 holding.
  • Gen-Wealth Partners first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Gen-Wealth Partners's CRISPR Therapeutics position peaked at $1.09K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.